This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Novartis Settles Henrietta Lacks Lawsuit
Business legal settlement

Novartis Settles Henrietta Lacks Lawsuit

Analysis based on 10 articles · First reported Feb 26, 2026 · Last updated Feb 28, 2026

Sentiment
20
Attention
4
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The settlement by Novartis resolves a significant legal and ethical issue, potentially reducing future litigation risk for the company. For the broader pharmaceutical and biotechnology industries, these settlements highlight the increasing scrutiny and potential financial liabilities associated with historical practices concerning biological materials, prompting companies to review their ethical sourcing and compensation policies.

Pharmaceuticals Biotechnology Healthcare
Event Summary

Novartis has settled a lawsuit with the estate of Henrietta Lacks, who alleged the pharmaceutical giant unjustly profited from her cells (HeLa cells) taken without her knowledge in 1951. These cells were instrumental in numerous medical advancements, including vaccines for polio and COVID-19. The terms of the settlement, finalized in federal court in Maryland, remain undisclosed. This marks the second such settlement for the Henrietta Lacks estate, following a 2023 agreement with Thermo Fisher Scientific. The estate has also filed pending lawsuits against Ultragenyx and Viatris, indicating a broader effort to seek compensation for the unauthorized commercialization of HeLa cells. The case underscores ethical concerns in medical research and the historical exploitation of Black patients.

Entities Involved
per
Henrietta Lacks
Henrietta Lacks' cells, taken without her consent in 1951, became the first immortalized human cell line (HeLa cells) and were crucial for countless medical advancements. Her estate has been actively pursuing legal action to seek compensation for the unauthorized use of her cells.
Importance 100.0 Sentiment 50.0
stock
Novartis
Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Importance 90.0 Sentiment 10.0
stock
Thermo Fisher Scientific
Thermo Fisher Scientific previously reached an undisclosed settlement with the estate of Henrietta Lacks in 2023 for commercializing HeLa cells without compensation to the family.
Importance 60.0 Sentiment 10.0
stock
Ultragenyx
Ultragenyx is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Importance 40.0 Sentiment 0.0
stock
Viatris
Viatris is currently facing a pending lawsuit from the estate of Henrietta Lacks regarding the use of HeLa cells.
Importance 40.0 Sentiment 0.0
cnt
United States
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.